AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$AUPH

Robertson Stephen P. sold $190K of AUPH

Robertson Stephen P. (Chief Legal Officer) sold 11,939 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.95 ($0.19M total) on 2026-09-10.

Original reporting
SEC EDGAR · Robertson Stephen P.
Published Sep 11, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AUPH
Neutral
high confidence
Mentioned
$AUPH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market relevance.

02

Market read

Minor insider sale; unlikely to affect Aurinia's stock price.

03

What to watch

No additional corporate actions or news accompany the filing.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$AUPHNeutralHigh confidence
Context

Chief Legal Officer Stephen P. Robertson sold 11,939 shares for $190,427, reducing his stake to 588,848 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is modest relative to float and typical insider transactions; market likely to view as routine.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could signal insider concern, but size is too small to be meaningful.

Key entities

  • Company
    Aurinia Pharmaceuticals Inc.

    Biopharmaceutical company listed on NASDAQ under ticker AUPH.

  • Individual
    Stephen P. Robertson

    Chief Legal Officer of Aurinia Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUPH insider trading history →

Related articles

SEP 17
$AUPHMed

Aurinia Stock Jumps After Earnings Beat And Pipeline Progress

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M and net income of $37.4M, with LUPKYNIS sales at $79.4M. The company initiated new clinical studies for aritinercept. Analysts forecast revenue of $453.5M and earnings of $169.9M by 2029, with a 7% upside potential. The stock rose on earnings beat and pipeline progress.

simplywall.st2 min
SEP 16
$AUPHMed

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.

yahoo.com2 min
AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min